Compare ARK Genomic Revolution ETF (ARKG) vs Procter & Gamble Co (PG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Procter & Gamble Co — how do they compare? ARK Genomic Revolution ETF trades at $41, while Procter & Gamble Co trades at $147.08 (market cap $342.40B). The key difference: Procter & Gamble Co pays a 2.9% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Procter & Gamble Co nearer its low. Which is the better fit depends on your goals.
| ARKG | PG | |
|---|---|---|
Sector | Sector/Thematic | Consumer Staples |
52-Week High | $43.57 | $167.18 |
52-Week Low | $23.09 | $138.10 |
Market Cap | — | $342.40B |
Volume | — | 6,423,436 |
Enterprise Value | — | $367.88B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Procter & Gamble (PG) trades at $147.04, up 0.13% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $1.42. Revenue for 2025 reached $84.28 billion, with a net income margin of 19.16%. Analysts maintain a consensus Buy rating, with a price target of $159.75, suggesting potential upside. Recent news highlights PG's dividend reliability and supply chain improvements.
PG offers a stable investment with strong fundamentals and a history of dividend growth, but faces risks from premium valuation and modest revenue growth. The stock's near-term performance may hinge on Q2 earnings and macroeconomic trends, with support at $146 providing a cushion against declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
